Literature DB >> 29780707

Precision radiotherapy for patients with locally advanced non-small cell lung cancer in the era of immunotherapy and precision medicine.

Hidehito Horinouch1.   

Abstract

Entities:  

Year:  2018        PMID： 29780707      PMCID： PMC5943228          DOI： 10.21037/tlcr.2018.03.13

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  13 in total

1.  Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.

Authors:  Yoshihiko Segawa; Katsuyuki Kiura; Nagio Takigawa; Haruhito Kamei; Shingo Harita; Shunkichi Hiraki; Yoichi Watanabe; Keisuke Sugimoto; Takuo Shibayama; Toshiro Yonei; Hiroshi Ueoka; Mitsuhiro Takemoto; Susumu Kanazawa; Ichiro Takata; Naoyuki Nogami; Katsuyuki Hotta; Akio Hiraki; Masahiro Tabata; Keitaro Matsuo; Mitsune Tanimoto
Journal:  J Clin Oncol       Date:  2010-06-07       Impact factor: 44.544

2.  The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo.

Authors:  B Roswit; M E Patno; R Rapp; A Veinbergs; B Feder; J Stuhlbarg; C B Reid
Journal:  Radiology       Date:  1968-04       Impact factor: 11.105

3.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

Authors:  Liufu Deng; Hua Liang; Byron Burnette; Michael Beckett; Thomas Darga; Ralph R Weichselbaum; Yang-Xin Fu
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

4.  Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.

Authors:  Mark A Socinski; David E Morris; Jan S Halle; Dominic T Moore; Thomas A Hensing; Steven A Limentani; Robert Fraser; Maureen Tynan; Andrea Mears; M Patricia Rivera; Frank C Detterbeck; Julian G Rosenman
Journal:  J Clin Oncol       Date:  2004-11-01       Impact factor: 44.544

5.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.

Authors:  Jeffrey D Bradley; Rebecca Paulus; Ritsuko Komaki; Gregory Masters; George Blumenschein; Steven Schild; Jeffrey Bogart; Chen Hu; Kenneth Forster; Anthony Magliocco; Vivek Kavadi; Yolanda I Garces; Samir Narayan; Puneeth Iyengar; Cliff Robinson; Raymond B Wynn; Christopher Koprowski; Joanne Meng; Jonathan Beitler; Rakesh Gaur; Walter Curran; Hak Choy
Journal:  Lancet Oncol       Date:  2015-01-16       Impact factor: 41.316

6.  Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer.

Authors:  Hidehito Horinouchi; Ikuo Sekine; Minako Sumi; Kazumasa Noda; Koichi Goto; Kiyoshi Mori; Tomohide Tamura
Journal:  Cancer Sci       Date:  2012-11-08       Impact factor: 6.716

7.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

8.  Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity.

Authors:  Hidehito Horinouchi; Yasushi Goto; Shintaro Kanda; Yutaka Fujiwara; Hiroshi Nokihara; Noboru Yamamoto; Minako Sumi; Tomohide Tamura; Yuichiro Ohe
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-09-26       Impact factor: 7.038

9.  PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Suresh Senan; Anthony Brade; Lu-Hua Wang; Johan Vansteenkiste; Shaker Dakhil; Bonne Biesma; Maite Martinez Aguillo; Joachim Aerts; Ramaswamy Govindan; Belén Rubio-Viqueira; Conrad Lewanski; David Gandara; Hak Choy; Tony Mok; Anwar Hossain; Neill Iscoe; Joseph Treat; Andrew Koustenis; Bélen San Antonio; Nadia Chouaki; Everett Vokes
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

10.  Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.

Authors:  Feng-Ming Kong; Randall K Ten Haken; Matthew Schipper; Kirk A Frey; James Hayman; Milton Gross; Nithya Ramnath; Khaled A Hassan; Martha Matuszak; Timothy Ritter; Nan Bi; Weili Wang; Mark Orringer; Kemp B Cease; Theodore S Lawrence; Gregory P Kalemkerian
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.